BAKER BROS. ADVISORS LP
Institutional investor · Portfolio as of Q1 2025
Top Holdings89 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
BEIGENE LTD-ADR | 8.8M | $2.4B | 26.5% | $149.13 | +79.30% | 25 qtrssince 2019-Q1 | Decreased 0 |
INCYTE CORP | 30.7M | $1.9B | 20.6% | $85.04 | -28.74% | 25 qtrssince 2019-Q1 | Increased 62 |
ACADIA Pharmaceuticals Inc. | 42.9M | $712.2M | 7.9% | $27.49 | -37.92% | 25 qtrssince 2019-Q1 | Unchanged 0 |
MADRIGAL PHARMACEUTICALS INC | 2M | $654M | 7.2% | $143.08 | +129.15% | 25 qtrssince 2019-Q1 | Unchanged 0 |
SUMMIT THERAPEUTICS INC | 24.4M | $471.2M | 5.2% | $8.44 | +140.63% | 4 qtrssince 2024-Q2 | Unchanged 0 |
INSMED INC | 5.4M | $410.5M | 4.5% | $65.66 | +18.79% | 25 qtrssince 2019-Q1 | Increased 62 |
RHYTHM PHARMACEUTICALS INC | 5.6M | $296.9M | 3.3% | $23.84 | +129.85% | 25 qtrssince 2019-Q1 | Decreased 0 |
REVOLUTION MEDICINES INC | 7.9M | $280.7M | 3.1% | $28.63 | +30.45% | 17 qtrssince 2021-Q1 | Unchanged 0 |
KYMERA THERAPEUTICS INC | 6M | $164.1M | 1.8% | $27.87 | +6.26% | 19 qtrssince 2020-Q3 | Unchanged 0 |
ALKERMES PLC | 4.5M | $148M | 1.6% | $24.70 | +33.68% | 4 qtrssince 2024-Q2 | Increased 51 |
EDGEWISE THERAPEUTICS INC | 6.2M | $135.4M | 1.5% | $16.18 | +43.79% | 17 qtrssince 2021-Q1 | Unchanged 0 |
Replimune Group, Inc. | 11M | $107.7M | 1.2% | $13.47 | -22.88% | 20 qtrssince 2020-Q2 | Unchanged 0 |
| 42.9M | $101.6M | 1.1% | — | — | — | Unchanged 0 | |
IMMUNOVANT INC | 5.5M | $93.3M | 1.0% | $21.82 | -15.81% | 7 qtrssince 2023-Q3 | Increased 76 |
BICYCLE THERAPEUTICS PLC | 10.9M | $92.4M | 1.0% | $20.84 | -56.96% | 11 qtrssince 2022-Q3 | Unchanged 0 |
IMMUNOCORE HLDGS PLC | 2.3M | $68.9M | 0.8% | $38.47 | -23.10% | 17 qtrssince 2021-Q1 | Increased 58 |
KINIKSA PHARMACEUTICALS INTL | 2.8M | $62.6M | 0.7% | $18.67 | +23.67% | 4 qtrssince 2024-Q2 | Unchanged 0 |
ABCELLERA BIOLOGICS INC | 27.5M | $61.4M | 0.7% | $18.96 | -87.82% | 18 qtrssince 2020-Q4 | Unchanged 0 |
Ultragenyx Pharmaceutical, Inc. | 1.6M | $57.1M | 0.6% | $70.98 | -46.72% | 18 qtrssince 2020-Q4 | Unchanged 0 |
DENALI THERAPEUTICS INC | 3.7M | $50.7M | 0.6% | $23.58 | -37.33% | 21 qtrssince 2020-Q1 | Unchanged 0 |
BAKER BROS. ADVISORS LP manages $9B across 89 positions as of Q1 2025. Top holdings: ONC (26.5%), INCY (20.6%), ACAD (7.9%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3.5/5.0.
Active quarter - 4 new positions, 10 exits, 11 increased. Top move: IMVT (INCREASED, conviction 76). Portfolio: $9.0B across 89 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer